PhRMA Urges Antitrust Exemption For Bioterrorism Research
Executive Summary
An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says
You may also be interested in...
BioShield Funding: Aventis Prefers Production Deals, Not R&D Support
Aventis-Pasteur would prefer a guaranteed manufacturing agreement rather than incremental payments for bioterrorism countermeasures developed under "Project BioShield.
BioShield Should Extend Liability Protection To Unapproved Products – BIO
Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said
“Project BioShield”: Industry Has Concerns, FDA Offers Support
A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies